Jiusheng Deng, PhD

Research Program

Discovery and Developmental Therapeutics
Phone Number

404-778-1763
Email Address

jdeng2@emory.edu

Biography

Jiusheng Deng, PhD, is an instructor in the Department of Pathology and Laboratory Medicine at Emory University School of Medicine. Dr. Deng is a member of the Discovery and Developmental Therapeutics Research Program at Winship Cancer Institute of Emory University in Atlanta, Georgia.

Education

Dr. Deng received his PhD from Tel Aviv University School of Medicine in Israel. He completed his postdoc training in Massachusetts General Hospital Harvard Medical School and Emory University. He then worked as a Research Associate in Stanford University School of Medicine. In 2011, Dr. Deng became an Instructor of Hematology and Medical Oncology in Winship Cancer Institute at Emory University.

Titles & Roles

Instructor, Department of Pathology and Laboratory Medicine

Emory University School of Medicine

Professional Memberships

Dr. Deng is an active member of the American Society of Hematology, American Association of Cancer Research and Society for Immunotherapy of Cancer.

Research

Dr. Deng's research focuses on developing novel immune therapeutics against cancers; in particular, he is interested in the utilization of bioengineered fusion cytokines to reprogram patient immune cells for personalized cancer immunotherapy.

Publications

He has authored a number of peer-reviewed publications in the elite journals such as Cancer Research, Molecular Cancer, Circulation, Nature Medicine and Nature Immunology.

Title/Journal	Authors	Publication Date
Silence of FIZZ1 by Short Hairpin RNA Inhibits Atherosclerosis. Annals of clinical and laboratory science	F Tang, F Yang, T Li, Y Yang, J Deng	01/03/2022
Erythropoietic properties of human induced pluripotent stem cells-derived red blood cells in immunodeficient mice. American journal of hematology	J Deng, M Lancelot, R Jajosky, Q Deng, K Deeb, N Saakadze, Y Gao, D Jaye, S Liu, SR Stowell, L Cheng, JD Roback	01/02/2022
BMI1 enables extensive expansion of functional erythroblasts from human peripheral blood mononuclear cells. Molecular therapy : the journal of the American Society of Gene Therapy	S Liu, M Wu, M Lancelot, J Deng, Y Gao, JD Roback, T Chen, L Cheng	05/05/2021
Silencing of long non-coding RNA H19 downregulates CTCF to protect against atherosclerosis by upregulating PKD1 expression in ApoE knockout mice. Aging	Y Yang, F Tang, F Wei, L Yang, C Kuang, H Zhang, J Deng, Q Wu	22/11/2019
Next-generation sequencing specifies Angiostrongylus eosinophilic meningoencephalitis in infants: Two case reports. Medicine	M Xie, Z Zhou, S Guo, Z Li, H Zhao, J Deng	01/08/2019
Crim1 suppresses left ventricular hypertrophy. Biomedical reports	L Yang, J He, G Xia, J Yang, Q Tang, Y Yang, J Deng	01/06/2019
Combination of serum lipids and cancer antigens as a novel marker for colon cancer diagnosis. Lipids in health and disease	T Li, Y Qian, H Li, J Deng	20/11/2018
Monocyte chemotactic protein-induced protein-1 enhances DR5 degradation and negatively regulates DR5 activation-induced apoptosis through its deubiquitinase function. Oncogene	YT Oh, G Qian, J Deng, SY Sun	01/06/2018
The proteasome deubiquitinase inhibitor b-AP15 enhances DR5 activation-induced apoptosis through stabilizing DR5. Scientific reports	YT Oh, L Deng, J Deng, SY Sun	14/08/2017
GM-CSF and IL-4 Fusion Cytokine Induces B Cell-Dependent Hematopoietic Regeneration. Molecular therapy : the journal of the American Society of Gene Therapy	J Deng, Y Li, A Pennati, S Yuan, JH Wu, EK Waller, J Galipeau	01/02/2017
Regulatory B Cells Induce Formation of IL-10-Expressing T Cells in Mice with Autoimmune Neuroinflammation. The Journal of neuroscience : the official journal of the Society for Neuroscience	A Pennati, S Ng, Y Wu, JR Murphy, J Deng, S Rangaraju, S Asress, JL Blanchfield, B Evavold, J Galipeau	14/12/2016
Expression of Death Receptor 4 Is Positively Regulated by MEK/ERK/AP-1 Signaling and Suppressed upon MEK Inhibition. The Journal of biological chemistry	W Yao, YT Oh, J Deng, P Yue, L Deng, H Huang, W Zhou, SY Sun	07/10/2016
Stimulation of Natural Killer Cell-Mediated Tumor Immunity by an IL15/TGFβ-Neutralizing Fusion Protein. Cancer research	S Ng, J Deng, R Chinnadurai, S Yuan, A Pennati, J Galipeau	01/10/2016
Paradoxical activation of MEK/ERK signaling induced by B-Raf inhibition enhances DR5 expression and DR5 activation-induced apoptosis in Ras-mutant cancer cells. Scientific reports	YT Oh, J Deng, P Yue, SY Sun	25/05/2016
BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth. Oncotarget	J Deng, D Park, M Wang, A Nooka, Q Deng, S Matulis, J Kaufman, S Lonial, LH Boise, J Galipeau, X Deng	10/05/2016
GIFT4 fusokine converts leukemic B cells into immune helper cells. Journal of translational medicine	J Deng, A Pennati, JB Cohen, Y Wu, S Ng, JH Wu, CR Flowers, J Galipeau	27/04/2016
Inhibition of B-Raf/MEK/ERK signaling suppresses DR5 expression and impairs response of cancer cells to DR5-mediated apoptosis and T cell-induced killing. Oncogene	YT Oh, J Deng, P Yue, TK Owonikoko, FR Khuri, SY Sun	28/01/2016
The novel proteasome inhibitor carfilzomib activates and enhances extrinsic apoptosis involving stabilization of death receptor 5. Oncotarget	B Han, W Yao, YT Oh, JS Tong, S Li, J Deng, P Yue, FR Khuri, SY Sun	10/07/2015
Incorporation of a GPI-anchored engineered cytokine as a molecular adjuvant enhances the immunogenicity of HIV VLPs. Scientific reports	H Feng, H Zhang, J Deng, L Wang, Y He, S Wang, R Seyedtabaei, Q Wang, L Liu, J Galipeau, RW Compans, BZ Wang	07/07/2015
Blood B Cell and Regulatory Subset Content in Multiple Sclerosis Patients. Journal of multiple sclerosis	J Habib, J Deng, N Lava, W Tyor, J Galipeau	01/05/2015
B cells for cancer immunotherapy. Oncoimmunology	J Deng, J Galipeau	01/11/2014
Engineered fusokine GIFT4 licenses the ability of B cells to trigger a tumoricidal T-cell response. Cancer research	J Deng, S Yuan, A Pennati, J Murphy, JH Wu, D Lawson, J Galipeau	01/08/2014
Silence of MCL-1 upstream signaling by shRNA abrogates multiple myeloma growth. Experimental hematology & oncology	M Wang, D Wu, P Liu, J Deng	01/01/2014
Maltose-binding protein fusion allows for high level bacterial expression and purification of bioactive mammalian cytokine derivatives. PloS one	A Pennati, J Deng, J Galipeau	01/01/2014
Reprogramming of B cells into regulatory cells with engineered fusokines. Infectious disorders drug targets	J Deng, J Galipeau	01/06/2012
A MCP1 fusokine with CCR2-specific tumoricidal activity. Molecular cancer	M Rafei, J Deng, MN Boivin, P Williams, SM Matulis, S Yuan, E Birman, K Forner, L Yuan, C Castellino, LH Boise, TJ MacDonald, J Galipeau	24/09/2011
Blocking the NOTCH pathway inhibits vascular inflammation in large-vessel vasculitis. Circulation	K Piggott, J Deng, K Warrington, B Younge, JT Kubo, M Desai, JJ Goronzy, CM Weyand	25/01/2011
Journal of Cardiovascular Disease Research celebrates its anniversary. Journal of cardiovascular disease research	J Deng	01/01/2011
Toll-like receptor 2-dependent induction of vitamin A-metabolizing enzymes in dendritic cells promotes T regulatory responses and inhibits autoimmunity. Nature medicine	S Manicassamy, R Ravindran, J Deng, H Oluoch, TL Denning, SP Kasturi, KM Rosenthal, BD Evavold, B Pulendran	01/04/2009
Toll-like receptors 4 and 5 induce distinct types of vasculitis. Circulation research	J Deng, W Ma-Krupa, AT Gewirtz, BR Younge, JJ Goronzy, CM Weyand	27/02/2009
Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nature immunology	TD Querec, RS Akondy, EK Lee, W Cao, HI Nakaya, D Teuwen, A Pirani, K Gernert, J Deng, B Marzolf, K Kennedy, H Wu, S Bennouna, H Oluoch, J Miller, RZ Vencio, M Mulligan, A Aderem, R Ahmed, B Pulendran	01/01/2009